10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript
10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript
TXG - 10x Genomics, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$22.43
DETAILS
HIGH:
$30.00
LOW:
$17.00
MEDIAN:
$22.00
CONSENSUS:
$22.43
DOWNSIDE:
5.28%
Stock News
This $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116%
10x Genomics provides advanced tools for single cell and spatial biology research, serving academic and biopharma institutions worldwide.
Torex Gold Resources Inc. (TXG:CA) Q1 2026 Earnings Call Transcript
Torex Gold Resources Inc. (TXG:CA) Q1 2026 Earnings Call Transcript
10x Genomics Q1 Earnings Call Highlights
10x Genomics NASDAQ: TXG reported a first-quarter revenue increase excluding prior-year settlement revenue and used its earnings call to emphasize the launch of Atera, a new spatial biology instrument platform that management described as the most significant product introduction in the company's history.
10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up
TXG beats Q1 estimates as consumables growth, margin expansion and lower operating costs narrow losses year over year.
10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript
10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript
10x Genomics (TXG) Reports Q1 Loss, Beats Revenue Estimates
10x Genomics (TXG) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.36 per share a year ago.
10x Genomics (TXG) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
10x Genomics Reports First Quarter 2026 Financial Results
PLEASANTON, Calif., May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026.
10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference
PLEASANTON, Calif., April 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, at 5:00 p.m.
LiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor
SAN CARLOS, Calif.--(BUSINESS WIRE)--LiquidCell Dx, a precision diagnostics company building a blood-based platform for tumor microenvironment profiling, today announced the appointment of Mirna Jarosz as Chief Executive Officer and Vincent A. Miller, MD, as Senior Strategic Advisor. The appointments add operating, commercialization and clinical leadership as the company advances its platform and prepares for the next stage of growth. Comprehensive genomic profiling changed oncology by making t.
10x Genomics Stock Up on Atera Launch, Spatial Biology Scale Enhanced
TXG stock jumps after unveiling Atera, a next-gen spatial biology platform aiming to scale single-cell analysis and deepen its role in drug discovery and research.
10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood
Enables Whole-Transcriptome In Situ Spatial Biology with Single-Cell Sensitivity at Scale Debuts at AACR Annual Meeting 2026 with Data from Leading Research Institutions, Including the June Lab at the Perelman School of Medicine, University of Pennsylvania and German Cancer Research Institute (DKFZ) PLEASANTON, Calif., April 18, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced Atera, a new in situ spatial biology platform engineered to deliver whole-transcriptome spatial analysis with single-cell sensitivity at unprecedented scale.
Analyzing Hinge Health (NYSE:HNGE) and 10x Genomics (NASDAQ:TXG)
Hinge Health (NYSE: HNGE - Get Free Report) and 10x Genomics (NASDAQ: TXG - Get Free Report) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations. Profitability This table compares Hinge Health and
10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026
PLEASANTON, Calif., April 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2026 after market close on Thursday, May 7, 2026.
Comparing 10x Genomics (NASDAQ:TXG) and HeartSciences (NASDAQ:HSCS)
10x Genomics (NASDAQ: TXG - Get Free Report) and HeartSciences (NASDAQ: HSCS - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation. Institutional and Insider Ownership 84.7% of 10x Genomics shares
Aaron Wealth Advisors LLC Has $1.08 Million Stock Holdings in 10x Genomics $TXG
Aaron Wealth Advisors LLC raised its holdings in 10x Genomics (NASDAQ: TXG) by 68.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 66,414 shares of the company's stock after acquiring an additional 26,884 shares during the quarter. Aaron Wealth Advisors
10x Genomics (NASDAQ:TXG) Shares Gap Up on Analyst Upgrade
Shares of 10x Genomics (NASDAQ: TXG - Get Free Report) gapped up prior to trading on Tuesday after William Blair upgraded the stock from a market perform rating to an outperform rating. The stock had previously closed at $19.81, but opened at $21.00. 10x Genomics shares last traded at $20.9670, with a volume of 150,356 shares
10x Genomics Seen As Key Player In AI-Driven Biological Data Buildout
• 10x Genomics shares are powering higher. What's fueling TXG momentum?
Price Targets
10x Genomics price target raised to $22 from $20 at Morgan Stanley
$22.00
(was $20.60)
Morgan Stanley
10x Genomics price target raised to $30 from $22 at Barclays
$30.00
(was $23.58)
Barclays
10X Genomics (TXG) PT Raised to $25 at Stifel on Solid New Product Adoption
$25.00
(was $22.38)
Daniel Arias
·
Stifel Nicolaus
10x Genomics price target raised to $20 from $14 at UBS
$20.00
(was $19.19)
UBS
10x Genomics price target raised to $17 from $16 at Deutsche Bank
$17.00
(was $19.40)
Deutsche Bank
10x Genomics price target raised to $20 from $15 at Stifel
$20.00
(was $17.51)
Stifel Nicolaus
10x Genomics price target raised to $22 from $20 at Canaccord
$22.00
(was $17.51)
Kyle Mikson
·
Canaccord Genuity
10X Genomics (TXG) PT Raised to $21 at BofA Securities
$21.00
(was $20.46)
Needham
10x Genomics price target raised to $20 from $19 at Canaccord
$20.00
(was $16.05)
Canaccord Genuity
10x Genomics price target raised to $22 from $17 at Barclays
$22.00
(was $15.45)
Barclays
10x Genomics assumed at Equal Weight from Overweight at Morgan Stanley
$20.00
(was $18.08)
Kallum Titchmarsh
·
Morgan Stanley
10x Genomics price target raised to $16 from $15 at Canaccord
$16.00
(was $12.39)
Kyle Mikson
·
Canaccord Genuity
10x Genomics price target raised to $13 from $12 at UBS
$13.00
(was $12.03)
Dan Leonard
·
UBS
10x Genomics price target raised to $14 from $10 at Deutsche Bank
$14.00
(was $12.29)
Justin Bowers
·
Deutsche Bank
10x Genomics price target lowered to $46 from $50 at Morgan Stanley
$46.00
(was $19.65)
Tejas Savant
·
Morgan Stanley
10x Genomics price target lowered to $32 from $50 at Canaccord
$32.00
(was $18.11)
Kyle Mikson
·
Canaccord Genuity
Deutsche downgrades 10x Genomics on demand erosion from competition
$25.00
(was $18.25)
Justin Bowers
·
Deutsche Bank
10x Genomics price target lowered to $24 from $36 at Barclays
$24.00
(was $19.85)
Luke Sergott
·
Barclays
Jefferies Starts 10X Genomics (TXG) at Hold
$24.00
(was $22.42)
Tycho Peterson
·
Jefferies
10x Genomics price target lowered to $36 from $45 at Barclays
$36.00
(was $29.28)
Luke Sergott
·
Barclays